Saama closes $40M funding round for its clinical trial AI platform

money
The Californian company has now raised $75 million since 2015. (Pixabay)

California data analytics company Saama Technologies has raised $40 million as it looks to bolster its artificial technology platform to “disrupt” clinical trials.

The cash boost, coming out of Perceptive Advisors, will be used to support the expansion of Saama’s Life Science Analytics Cloud (LSAC), an AI-powered platform that the company says “seamlessly ingests, integrates, curates and harmonizes clinical trial operational and patient data from proprietary and external data sources to deliver actionable, regulatory-ready insights.”

In essence, it’s using a data analytics approach to help speed up clinical trials and drugs to the market more quickly for its clients. It’s raised $75 million toward this goal since 2015.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suresh Katta, founder and CEO of Saama Technologies, said, “The pharmaceutical industry, patients, advocacy groups and global regulatory agencies are all eager for innovations that rapidly accelerate clinical trials while driving down costs.

“We are excited to lead that change with a differentiated data analytics platform. We intend to use the proceeds of this financing to strengthen our ecosystem of pharma and biotech partners, academia, data providers and CROs, and build a suite of collective innovations leveraging our award-winning LSAC platform.”

“Perceptive’s investment in Saama will enable this leading data analytics company to continue to innovate at the highest level,” added Sam Chawla, portfolio manager, Perceptive Advisors. “Partnering with Saama at this exciting juncture in the company’s lifecycle opens up a spectrum of future opportunities for Saama to positively impact clinical operations and influence business outcomes for life sciences companies.”

Saama’s life science solution is based on a data analytics platform. It includes the Trial Planning Optimizer, which uses real-world data to identify eligible patient and investigator, evaluate the success rate of patient enrollment and site selection, and identify protocol design problems that may affect recruitment. It also has a cohort generation solution that uses real-world patient information to identify target population groups that could fit inclusion-exclusion criteria.

RELATED: Elligo, Saama join forces to develop new clinical trial data management platform

Last year, it penned a pact with Elligo Health Research that saw the pair combine their clinical trial support software to create a new platform, designed to improve clinical research data management.

By joining forces, the partnership aims to help trial sponsors assemble vast amounts of data from disparate sources and to transform the way submission data is produced by using dashboards, analytics and reporting.

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.